1	Trajectories of mHealth-tracked mental health symptoms and
2	their predictors in chronic pelvic pain
3	Emily L. Leventhal, B.A., <sup>1,2</sup> Nivedita Nukavarapu, Ph.D., <sup>1,2</sup> Noemie Elhadad, Ph.D., <sup>3</sup> Suzanne
4	Bakken, Ph.D., RN, FAAN, FACMI, FIAHSI, <sup>4</sup> Michal Elovitz, M.D., <sup>6</sup> Robert Hirten, M.D., <sup>7</sup>
5	Jovita Rodrigues, M.S., <sup>1,2</sup> Matteo Danieletto, Ph.D., <sup>1,2</sup> Kyle Landell, B.A., <sup>1,2</sup> and Ipek Ensari,
6	Ph.D. <sup>1,2</sup>
7	
8	<sup>1</sup> Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount
9	Sinai, New York, NY, USA
10	<sup>2</sup> Hasso Plattner Institute for Digital Health Mount Sinai, New York, NY, USA
11	<sup>3</sup> Department of Biomedical Informatics, Columbia University Irving Medical Center, New York,
12	NY, USA
13	<sup>4</sup> Columbia University School of Nursing, Columbia University Irving Medical Center, New York,
14	NY, USA
15	<sup>6</sup> Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at
16	Mount Sinai, New York, NY, USA
17	<sup>7</sup> The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at The
18	Mount Sinai Hospital, New York, NY, USA
19	
20	

21

#### Abstract

Background. Female chronic pelvic pain disorders (CPPDs) affect 1 in 7 women 22 23 worldwide and are characterized by psychosocial comorbidities, including reduced quality of life 24 and 2-10 fold increased risk of depression and anxiety. Despite its prevalence and morbidity, 25 CPPDs are often inadequately managed with few patients experiencing relief from any medical 26 intervention. Characterizing mental health symptom trajectories and lifestyle predictors of 27 mental health is a starting point to enhancing patient self-efficacy in managing symptoms. Here, 28 we investigate the association between mental health, pain, and physical activity (PA) in females 29 with CPPD and demonstrate a method for handling multi-modal mobile health (mHealth) data. 30 Method. The study sample included 4,270 person-level days and 799 person-level weeks of data 31 from CPPD participants (N=76). Participants recorded PROMIS global mental health (GMH) 32 and physical functioning, and pain weekly for 14 weeks using a research mHealth app, and 33 moderate-to-vigorous PA (MVPA) was passively collected via activity trackers. Data analysis. We used penalized functional regression (PFR) to regress weekly GMH-T (GMH-T) on MVPA 34 35 and weekly pain outcomes, while adjusting for baseline measures, time in study, and the random intercept of the individual. We converted 7-day MVPA data into a single smooth using spline 36 37 basis functions to model the potential non-linear relationship. **Results**: MVPA was a significant, 38 curvilinear predictor of GMH-T (p<0.001), independent of pain measures and prior psychiatric diagnosis. Physical functioning was positively associated with GMH-T, while pain was 39 negatively associated with GMH-T ( $\beta$ =2.24,  $\beta$ =-1.16, respectively; p<0.05). Conclusion: These 40 41 findings suggest that engaging in MVPA is beneficial to the mental health of females with

42	CPPD. Additionally, this study demonstrates the potential of ambulatory mHealth-based data
43	combined with functional models for delineating inter-individual and temporal variability.
44	Keywords
45	Chronic pelvic pain; digital health; functional data modeling; global mental health.
46	Corresponding author
47	Emily Leventhal, B.A., 3 E 101st Street, New York, NY 10029,
48	emily.leventhal@icahn.mssm.edu
49	Introduction
50	Described as a "neglected reproductive health morbidity," chronic pelvic pain (CPP) is a
51	highly debilitating condition that affects between 5.7% and 26.6% of women worldwide. <sup>1–3</sup> CPP,
52	which encompasses complex CPP disorders (CPPDs) such as endometriosis, adenomyosis, and
53	fibroids, is characterized by non-cyclic pain in the pelvis or abdomen that lasts for at least 6
54	months and leads to functional disability or the necessity for medical intervention. <sup>3–5</sup> Its severity
55	is underscored by its associated physical, psychological, and emotional, and social
56	consequences. <sup>4,5</sup>
57	The strong psychosocial impact of CPPDs contributes to their morbidity. For example,
58	individuals with CPPDs are more likely to experience reduced quality of life, emotional well-
59	being, productivity, and sexual function compared to the general population. <sup>4</sup> Additionally,
60	CPPD patients have a significantly higher risk of comorbid psychiatric disorders. <sup>4,6,7</sup> . For
61	example, individuals with CPPDs have been reported to experience depressive disorders at a
62	prevalence of 2 to 10 times that of the general population and anxiety disorders 3 to 6 times that

of the general population.<sup>4</sup> Because chronic pain is tightly linked to mental health problems, 63 investigation of potentially modifiable predictors of mental well-being in individuals with 64 CPPDs may be a starting point for comprehensively managing and treating CPPD patients.<sup>8</sup> 65 Despite its prevalence and burden, CPP is often inadequately managed, with less than 66 half of patients experiencing pain relief from any medical treatment.<sup>6,9</sup> Patient self-management, 67 68 which encompasses active efforts to manage pain and its effects on physical and emotional 69 function, is a common chronic pain care model intervention, and it has been associated with significant improvement in symptoms.<sup>10,11</sup> Further, Center for Disease Control (CDC) guidelines 70 71 state that non-opioid and non-pharmacologic therapies should be prioritized for chronic pain management.<sup>12,13</sup> Non-pharmacological self-management strategies, especially those that target 72 73 mental health outcomes of CPPD patients, are needed for effective personalized treatment of CPPD. 74

75 Physical activity (PA), and exercise, defined as planned, structured, and repetitive PA with the goal of improved health or fitness, have been demonstrated to be effective pain self-76 77 management for both reducing pain severity and improving psychological function in chronic pain patients.<sup>11,14</sup> Experts recommend that chronic pain patients exercise on a regular schedule on 78 79 the premise that avoiding activity during pain and increasing intensity later may lead to pain flares.<sup>4</sup> Importantly, exercise is a modifiable behavior that can also improve pain self-efficacy, 80 defined as the confidence in one's ability to function effectively while in pain, which is 81 associated with improved quality of life.<sup>15,16</sup> Further, for chronic pain patients with comorbid 82 psychiatric conditions, exercise may improve mood, depression, and anxiety symptoms.<sup>4</sup> A 83

previous study with individuals with endometriosis estimated a small but statistically significant 84 favorable effect of exercise on pain severity.<sup>17</sup> However, this study relied on self-reported 85 exercise, which is limited in its ability to capture more granular PA parameters (eg, step counts, 86 intensity-level).<sup>17</sup> While most of the evidence connecting PA to psychosocial improvement has 87 88 been from other chronic pain conditions, yoga has previously been demonstrated to be efficacious for improving pain and quality of life for patients with endometriosis.<sup>4</sup> The impact of 89 90 broader PA on mental health in patients with CPP specifically remains to be investigated, with a 91 focus on using longitudinal data to capture potentially meaningful trends over time. 92 CPPDs and their symptomatic patterns are notably heterogeneous in clinical presentation both between patients and within-individuals over time.<sup>18</sup> Capturing these fluctuations under 93 ecologically valid circumstances can help improve our understanding of the dynamic unfolding 94 95 of these symptoms and their potential predictors. In the context of health behaviors such as PA, data from mobile health (mHealth) technologies (eg, smartphone apps, trackers) combined with 96 97 longitudinal analytic techniques can help elucidate symptom associations with psychosocial outcomes in CPP.<sup>7,18</sup> For example, there may be non-linear associations and cumulative effects 98 99 in these longitudinal data that are not possible to capture via linear modeling approaches. In sum, 100 flexible techniques can be particularly useful when considering variables that differ in sampling frequencies, missingness patterns, modality, and temporal complexity, which is often the case 101 102 with mHealth data. 103 Functional regression models, which are a part of the family of generalized additive

models (GAMs), constitute one such approach.<sup>19</sup> In a functional regression framework, the entire

105 data curve is considered as the unit of analysis, instead of discrete data points in a set of 106 longitudinal data. This is particularly useful for handling PA data from wearables, rather than aggregating multiple data points per individual,<sup>20</sup> as they allow investigating the associations 107 between scalar and functional variables with different time intervals. One example of a scenario 108 109 relevant to this study is consideration of continuous or daily PA data with weekly self-reported 110 survey data, in a repeated-measures design. This results in a data structure where each weekly 111 questionnaire corresponds to 7 days of PA data leading up to the survey data. A functional 112 regression model considers the PA data as a weekly data curve rather than aggregating the entire 113 week into a summary score and thus preserves the temporal pattern within the data. This can 114 reveal important information that may be lost otherwise, such as periods of inactivity or bursts of activity, which could be related to mental health.<sup>4,21</sup> 115 116 Accordingly, this study aims to characterize the patterns of association between self-

reported mental health symptoms and their predictors in CPPDs, with a focus on modifiable lifestyle factors. Specifically, this overall aim includes investigation of 1) between- and withinindividual fluctuations in weekly self-reported mental health, and 2) possible modifiable and trait predictors of weekly mental health. We hypothesized that there would be significant variability in the mental health both between and within individuals and that PA would be a positive nonlinear predictor of mental health.

123

## Methods

124 Study Design and Procedures

125 The study design and procedures were approved by the IRB of the Icahn School of 126 Medicine at Mount Sinai (ISMMS; IRB# STUDY-22-01002). This is a secondary analysis of the 127 data from an ongoing larger study that aims to design, develop, and evaluate CPPD-specific 128 mHealth measures from patient generated health data with high complexity and temporality 129 using non-linear distributed lag and functional data modeling (NIH/NICHD: R01HD108263). It 130 uses an observational study design to collect 90 days of data on patient self-tracked symptoms via a research mHealth app (ehive<sup>22</sup>) and passively collected activity data using activity trackers 131 132 from participants. All participants used the ehive research study app for providing the baseline 133 and weekly data on overall health, symptoms, well-being and health behaviors, as well as for receiving prompts and reminders about the study.<sup>22</sup> Participants were instructed to wear a Fitbit 134 135 for the duration of the study.

## 136 Study Sample

137 The study sample included individuals who met the following eligibility criteria for the parent study: 1) females who menstruate currently, between the ages of 18 and 64, 2) self-138 139 reported CPPD based on clinician diagnosis, 3) experience of CPP for at least 6 months, and 4) 140 ability to read and write in English. Exclusion criteria include: 1) current pregnancy, a birth in 141 the past 6 months, or planning pregnancy during the months of the study and 2) major diseases or 142 comorbidities (eg, active cancer, acute coronary syndrome within the past 3 months) that might 143 confound the outcomes of the primary pelvic pain-related condition. Participants were recruited 144 from all campuses of the Mount Sinai Health System (MSHS) and Columbia University Irving

Medical Center (CUIMC) via email advertisements and on the myChart by EPIC mobile app forMSHS patients.

#### 147 Enrollment

Interested patients reached out to the study coordinator at Mount Sinai for screening and enrollment, after which they were onboarded and oriented to the study app and data collection protocols. All participants were mailed a Fitbit Inspire 2 device and instructed to use for the duration of the study (90 days). Participants were remunerated \$15 for every 2 weeks of data collection and \$20 for the final week (ie, up to \$120 in total for completing 90 days of data collection). All participants provided informed consent prior to enrolling in the study.

## 154 Study Measures

## 155 **Primary Outcomes**

156 Self-reported mental health was assessed every week using the PROMIS Global Mental Health Questionnaire (GMH; 2a, v1.2).<sup>23</sup> The GMH includes 2 questions: 1) "In general, how 157 158 would you rate your mental health, including your mood and your ability to think?" 2) "In 159 general, how would you rate your satisfaction with your social activities and relationships?" Both 160 questions have a 5-point multiple choice response scale (1-not at all, 5-very much) and the 161 responses are added to compute the total score on the GMH (range 2-10). Higher scores represent better mental health.<sup>23</sup> The two-item GMH survey provides a brief measure of mental 162 health that has been found to be both reliable and have construct validity.<sup>23</sup> Scores from the 163 164 GMH survey have been positively associated with other self-reported outcomes including overall 165 quality of life and physical functioning, and negatively correlated with fatigue, anxiety, anger,

depressive symptoms, and chronic conditions (e.g., liver disease, kidney disease, hypertension,
etc.).<sup>23</sup> We converted raw GMH scores to population-standardized GMH scores (T-scores)
according to the PROMIS Global Health scoring manual by standardizing the raw total score to a
mean of 50 and a standard deviation (SD) of 10.<sup>24</sup> GMH T-scores (GMH-T) are further

170 categorized as excellent (>55), very good (48-55), good (40-47), fair (29-39), and poor (<29).<sup>25</sup>

171 **Predictors** 

172 **Physical activity.** Daily minutes of moderate-to-vigorous intensity PA (MVPA) and step 173 counts were obtained from the wrist-worn Fitbit devices. Participants were instructed to wear 174 their devices continuously for the study duration. The study app (ehive) allows the user to link their account with their Fitbit device,<sup>22</sup> which enables regular daily data synching on the backend 175 176 of the app. Fitbit uses its proprietary algorithms for detection of step counts and activity 177 intensities. We collected 6,341 days of physical activity data for 78 participants. For wear time 178 validation, we relied on the commonly used standard "10-hour minimum wear" rule, in which a valid day is defined as at least 10 hours of non-zero activity counts.<sup>26–28</sup> Ten hours of wear has 179 been shown to be sufficient to estimate total daily physical activity during non-sleep time.<sup>29</sup> 180 181 There were 4,301 valid days of Fitbit data for 76 participants. Days with unrealistically low 182 activity counts (eg, <500 steps in a day; n=14) were removed in accordance with similar cutoffs 183 that have been used in the past to define a valid day, although we used a more conservative cutoff.<sup>26,27</sup> This resulted in 4,287 days of physical activity data for 76 participants. If there were 184 185 more than 7 days of Fitbit data in between survey responses (ie, if a participant waited more than 186 7 days before completing the next survey), we only considered the first 7 days of Fitbit activity

data to avoid sparsity in the penalized functional regression (PFR) model (described below). 77
days of activity data measured more than 7 days after a survey response were removed for this
reason. The final dataset had 4,270 days of data for 76 participants.

190 **Physical functioning.** Weekly physical functioning scores were measured using the PROMIS physical function survey (4a, v1.0).<sup>30</sup> Physical functioning is the self-reported 191 192 capability of performing everyday physical activities. The score evaluates functioning of upper 193 extremities, lower extremities, central regions, and activities of daily living. The 4-item PROMIS 194 survey assesses the extent to which individuals find difficulty with physical tasks (5-without any 195 difficulty to 1-unable to do). Scores range from 4 to 20, with higher scores indicating better 196 physical functioning. We used the physical functioning T-scores in the analyses, which are standardized to a mean of 50 and a SD of 10 based on a representative population distribution.<sup>30</sup> 197 198 **Pain**. We measured weekly pain levels using the VAS pain intensity item from the shortform McGill Pain Questionnaire (MPQ-VAS).<sup>31</sup> The MPQ-VAS asks participants to rate the 199 intensity of their present pain intensity on a scale of 0 (no pain) to 100 (worst imaginable pain).<sup>32</sup> 200 201 This type of VAS-based pain assessment is commonly used as a standard practice in clinical settings to evaluate patient pain status and treatment outcomes.<sup>33,34</sup> 202

Other covariates. Data on personal demographics and general health were collected via a baseline questionnaire on the ehive app. We collected age, marital status, ethnicity, and employment status from the demographics survey. In addition, we used prior psychiatric diagnosis ("Have you ever been diagnosed with a psychiatric diagnosis by a provider?") as a covariate from the general health survey.

## 208 Data analysis

## 209 Descriptive and bivariate analyses

First, we performed descriptive analyses and investigated bivariate associations between 210 211 the weekly-measured survey items. Given the repeated-measures design, we use both person-212 level means (ie, a participant's mean score across the 14 weeks) and overall sample means (ie, 213 mean of means) where necessary to report the overall study average scores from the daily (ie, 214 steps, MVPA) and weekly (ie, pain, physical functioning T-score, GMH-T) measures. To 215 analyze the GMH-T, we converted the mean GMH-T for each participant to its corresponding 216 GMH category (eg, fair, good, excellent, etc.), and computed the percent of participants in each category.<sup>25</sup> To evaluate sample GMH-T and physical functioning T-scores against known 217 218 population means, we used a one-sample T-test to compare the sample means to the population 219 means. We then computed repeated-measures correlations between GMH-T, physical 220 functioning, MPQ-VAS, and the sum of MVPA over 7 days using the rmcorr R package, which 221 evaluates the within-individual association of paired measurements taken two or more times longitudinally.<sup>35</sup> 222

## 223 Multivariable regression analysis of GMH predictors

To investigate the potential predictors of GMH-T scores at the week level, we implemented PFR modeling using the R refund library.<sup>20</sup> PFR models are flexible in numerous ways that are particularly useful for the data in this study. First, they allow for entire data curves to be units of analysis as opposed to individual data points. Next, they accommodate different sampling intervals in the outcomes vs predictors, ie, week-level outcome (eg, GMH-T) and

week-level (eg, pain, physical functioning) and day-level (eg, MVPA) predictors. Instead of
aggregating multiple day-level MVPA values for each week, this feature of the PFR allows for
the preservation of temporal variability in MVPA over a week. Third, it allows specification of
random intercepts (ie, individual participants), which is useful for both accommodating a
repeated measures design and for investigation of potential between- vs within-individual
variability in the outcome of interest (ie, GMH-T scores).

235 We regressed GMH-T on MVPA while considering MPQ-VAS, PROMIS physical 236 functioning, age, marital status, employment status, and prior psychiatric diagnosis. We further 237 adjusted for time in study using month-level cyclical encoding, in which each date is mapped 238 into a cyclic coordinate system using sine-cosine waves and allows the models to infer the 239 distance between dates based on their sine-cosine coordinates. We converted 7-day MVPA data into smooths with up to 7 knots using the tensor product basis function<sup>36</sup> to model the potential 240 241 non-linear relationship between GMH-T and daily PA. We similarly included the time covariate as a functional smooth with up to 7 knots.<sup>20</sup> We scaled MPO-VAS, PROMIS physical 242 243 functioning, and age by mean-centering each variable and dividing by its standard deviation. We 244 included participant and week in study as random effects. Finally, other categorical variables (ie, 245 psychiatric diagnosis, employment status, and marital status) were included as person-level linear covariates.<sup>20</sup> We used a generalized additive model as the fitter to estimate the model and 246 restricted maximum likelihood as the smoothing parameter estimation method, which are the 247 248 default recommended methods for the function.<sup>20</sup>

249

Results

## 250 Study sample

251 Participants (n=76) provided 799 weeks of survey and 4,270 days of activity data in total 252 for analysis. Participants had a mean age of 35 years and were mostly employed (76%). Most 253 participants identified as White (42%) or Hispanic or Latino (17%). In our sample, 28% had at 254 least one prior diagnosis of a psychiatric condition, including anxiety and mood disorders (Table 255 1). The CPPD diagnoses included endometriosis (N=51), adenomyosis (N=1), uterine fibroids 256 (N=2), interstitial cystitis (N=1), inflammatory bowel syndrome (3), and inflammatory pelvic 257 dysfunction (N=1). 258 **Descriptive and bivariate analyses** 259 The overall sample means of the scores from the daily and weekly measures are reported 260 in Table 2. Thirty-nine percent of the participants, on average, reported scores that corresponded 261 to "fair" mental health, with another 39% of the participants on average reporting "good" mental 262 health (Table 2). The mean GMH-T was 42.166 (95% CI: 40.363-43.969), which is 7.83 SDs below the population mean (ie, M=50, "very good")<sup>23</sup> and significantly different (t=-8.658, p < 263 264 .001; Figure 1). The mean physical functioning T-score was 45.19 (95% CI: 43.52-46.853), 265 which is 0.48 SDs below the population mean (ie, M=50; Figure 1; t = -5.758, p < .001). 266 To characterize the PA patterns in the sample, we compared participants' activity levels 267 to the published recommendations and CDC/HHS PA guidelines for adults with respect to steps

and MVPA.<sup>37,37–39</sup> On average, participants accumulated 8,313 steps and 38 minutes of MVPA

269 per day (Table 2). Forty-three percent of the sample engaged in fewer than 7,500 daily steps,

270 which is the lower threshold recommended for being considered "sufficiently active" (Figure

2a). <sup>38,39</sup> Similarly, 40.9% accumulated fewer than 150 minutes of weekly MVPA recommended
by the PA Guidelines (Figure 2b).<sup>40</sup>

273	To inspect the bivariate associations between weekly measures, we computed repeated
274	measures correlations between GMH-T and the other variables. GMH-T were positively
275	correlated with weekly MVPA ( $p$ <.05), and physical function T-score ( $p$ <.01), while they were
276	negatively correlated with MPQ-VAS ( $p$ <.001; Figure 3). Weekly MVPA was additionally
277	positively correlated with physical functioning T-score ( $p$ <.05) but was not significantly
278	correlated with MPQ-VAS.
279	PFR model
280	We fitted a PFR model to the data to investigate cumulative and non-linear effects of
281	MVPA on the weekly GMH-T. The best fitting final model explained 72.6% of the variance in
282	GMH-T ( $R^2$ =0.65). The smooth of MVPA and time on GMH-T indicated a significant non-linear
283	relationship (Table S1; Table S2; edf=2.23, F=18.99, p<.001). Predicted GMH-T increased with
284	increasing daily MVPA minutes (Figure 4a). Over time, the largest positive effect of MVPA on
285	predicted GMH-T as reported at the end of the week was a few days prior (~day 4). The positive
286	effect of MVPA on GMH-T reported at the end of the week diminished after day 4, suggesting
287	the positive effects of MVPA lagged by a couple of days. Weekly MPQ-VAS was a significant
288	negative predictor of GMH-T ( $\beta$ =-1.16, SE=0.50, <i>t</i> =-2.34, <i>p</i> <.05), while physical functioning T-
289	score was a significant positive predictor of GMH-T (Figure 4b; Table S3; $\beta$ =2.24, SE=0.598,
290	<i>t</i> =3.75, <i>p</i> <.001). For demographic factors, age was negatively associated with GMH-T ( $\beta$ =-1.20,
291	SE=0.46, $t$ =-2.58, $p$ <.05), while being employed and married were positively associated with

GMH-T ( $\beta$ =4.01, SE=1.09, *t*=3.67, *p*<.001;  $\beta$ =3.60, SE=0.86, *t*=4.20, *p*<.001). Prior psychiatric diagnosis was not a significant predictor of weekly GMH. The random effect of participant was significant (Figure 4c; edf=33.43, *F*=2.76, *p*<0.001). The random effect of week and the cyclically encoded sine and cosine functions of month were not significant.

296

## Discussion

297 In this study, we leveraged ambulatory mHealth-tracked mental health, pain, and physical 298 activity data to characterize longitudinal self-reported mental health patterns of individuals with 299 CPPDs. Our results indicate a positive, non-linear relationship between PA and mental health, 300 independent of prior psychiatric diagnosis or other pain-related factors, with considerable 301 variability both between and within participants over time. To our knowledge, this study 302 provides the first line of evidence on the positive effect of PA on mental health in females with 303 CPPDs using repeated measures data collected in real time. We further report lower scores of 304 mental health and physical functioning compared to the general population, as well as lower PA 305 levels than those recommended by the PA guidelines.

Our cohort had a 28% incidence of prior psychiatric conditions and lower average global mental health compared to the general population. Chronic pain, and specifically CPPDs, has been established as a strong predisposing factor for psychiatric conditions, due to both the psychosocial impact of chronic pain and common neurobiological vulnerabilities and genetic factors between chronic pain and mood.<sup>4,6,41,42</sup> CPPD patients with comorbid psychiatric conditions are more likely to incur higher health care costs, experience lower quality of life, endure increased disability, and are more likely to be prescribed opioids.<sup>4</sup> Additionally, our

313 findings add to the literature documenting the worsened mental health of CPPD patients as a whole compared to the general population.<sup>4,23,42</sup> In the 2019 National Health Interview Survey, 314 315 those with chronic pain had a 23.9% prevalence of co-occurring anxiety and/or depression symptoms, whereas the population without chronic pain had a prevalence of 4.9%.<sup>42</sup> Given the 316 high incidence of psychiatric co-morbidities and the generally low mental health among CPPD 317 318 patients, it is important to treat mental health as part of comprehensive chronic pain management 319 and continue to determine ways to aid patients to manage their symptoms. As such, here, we 320 investigated how lifestyle factors may modify the association of CPP with poorer mental health 321 outcomes. 322 Our findings suggest that many females with CPPDs do not reach nationally 323 recommended activity levels, and moreover, that engaging in MVPA is beneficial for the mental 324 health of CPPD patients. The PA levels found in this sample are consistent with previous studies indicating that individuals with CPPDs have lower PA levels,<sup>43</sup> though data on CPPDs are 325 326 scarce. One longitudinal study using accelerometers indicated that MVPA negatively mediated 327 the relationship between chronic pain and risk of mental disorders, although this study did not focus on CPP.<sup>44</sup> Increased MVPA in individuals with chronic pain was associated with decreased 328 anxiety and depression symptoms, whereas light intensity PA did not have this effect.<sup>42</sup> While 329 330 previous studies have established the connection between MVPA and mental health in chronic 331 pain, this is the first study to establish the relationship between PA and mental health in the context of CPP by using passively-obtained data from activity trackers.<sup>17</sup> 332

333 Our findings further indicate that increased pain is associated with worsened GMH, while 334 increased physical functioning was associated with improved GMH. Though pain and depression 335 or anxiety have been noted to have a bidirectional relationship, there is more evidence that pain is a risk factor for mental health problems than the inverse.<sup>4</sup> Additionally, a longitudinal study 336 337 focused on musculoskeletal conditions found that improvements in physical functioning were 338 associated with improved anxiety symptoms, although it was not associated with improved depression symptoms.<sup>45</sup> The relationship between physical functioning and mental health in CPP 339 340 has not been well defined to this point, however, one previous longitudinal study on endometriosis reported that functional pain disability did not predict later emotional distress.<sup>46</sup> 341

342 With respect to demographic factors as potential predictors, increased age was associated 343 with worsened GMH, while prior psychiatric diagnosis was not a significant predictor. Age may 344 be a proxy for years of experience with the chronic pain condition or severity of the condition. In 345 this study, we did not have a survey item assessing time of initial diagnosis, although this may be 346 possible in the future by linking mobile health studies with electronic health records (EHRs). 347 Over time, chronic pain may become more difficult to treat due to structural and functional neuroplastic changes that eventually become irreversible and insensitive to treatment.<sup>41</sup> From a 348 349 psychosocial standpoint, the economic consequences of health care costs and loss of productivity may accumulate over time.<sup>41</sup> It will be important to assess how length of time of living with 350 351 chronic pain impacts mental health in the future. Interestingly, diagnosis with a prior psychiatric 352 condition, including mood and anxiety disorders, was not a significant predictor of GMH. This 353 may suggest that some individuals with prior psychiatric diagnoses may not be actively

experiencing symptoms, or alternatively, that this sample has a large number of participants withundiagnosed psychiatric conditions that are actively experiencing symptoms.

356 We observed substantial between- and within-individual variability in mental health 357 scores in the sample, underscoring the importance of personalized approaches to care. Predicted 358 average GMH-T varied greatly between individuals as shown by the random intercepts. CPPDs 359 are notoriously heterogeneous in pain symptomatology, and it follows that mental health would exhibit similar variability among and within participants.<sup>7</sup> As such, it is important to use 360 361 individualized approaches, such as that which may be achieved with mHealth, to 362 comprehensively understand the complexity of CPP. Due to their heterogeneous clinical 363 presentation and differing etiologies, CPPDs are often non-responsive to treatment, and a 364 personalized approach is necessary for the successful management of CPPD. To better 365 understand how to manage the mental health of CPPD patients, we should continue to study 366 modifiable lifestyle factors, as was done here with PA, that may alter the poor mental health 367 outcomes associated with CPP. This study demonstrates the potential of using ambulatory 368 mHealth-based data combined with functional data methods to delineate inter-individual and 369 temporal variability in symptoms of chronic conditions.

There are numerous strengths of this work. First, we focus on a patient population that has been under-studied (ie, CPPDs) and currently still not well-understood as a cluster of disorders with overlapping symptomatology. While endometriosis, the most common underlying primary diagnosis for a CPPD, has been receiving more attention recently, our sample also included those less-studied CPP conditions (eg, adenomyosis, fibroids, inflammatory pelvic

375 disease). Next, implementation of functional data methods and generalized additive modeling 376 using smooths provide robust, flexible approaches for handling the complex patient-generated health data from mHealth technologies. The PFR models in this context facilitate the evaluation 377 378 of complex relationships between outcomes and their predictors in instances where data 379 sampling frequency differs between the outcomes and predictors, or between different predictors. 380 As mHealth use is becoming more ubiquitous for conducting research, expanding upon the 381 available methods will enable fully harnessing the information from these data. Third, our 382 analyses were based on frequently-sampled prospective data of up to 14 weeks from the study 383 participants. This is a strength of the data design as most studies to date are limited to 384 convenience samples of retrospective data with much less frequency of data points. 385 Nevertheless, we acknowledge the limitations of this study. Although we had 799 person-386 level weeks for analysis, 76 participants is a relatively modest sample size in comparison to 387 large, nationally-representative cohort studies. Similarly, the sample was somewhat homogeneous with respect to demographic factors including employment status and education 388 389 levels. Third, despite our careful inspection of the missing data and implementing cautious 390 filtering criteria to prevent potentially erroneous inference from the data, Fitbit's proprietary 391 algorithms do not always enable as informed decisions regarding the missing data as do some 392 other devices, such as research grade trackers that allow access to the raw acceleration data. To 393 circumvent these issues, we conducted a series of sensitivity analyses to assess the pattern of 394 missingness in the data, as well as the possible influence of missingness on the model results. 395 Results (not reported herein) indicated no significant bias, suggesting a missing-at-random

396	(MAR) pattern, or change in model point estimates. Finally, most of the participants had
397	endometriosis as their primary CPPD, therefore we are not able to delineate differences in mental
398	health trajectories among different disorders within CPPD.
399	Conclusions
400	mHealth-enabled direct patient input and passive tracking via wearables enables the
401	capturing of real-world data to improve our understanding of inter-individual and temporal
402	variability in mental health symptoms and factors that may improve mental health. By leveraging
403	patient-tracked mental health and pain outcomes combined with passively-obtained activity data
404	from CPPD patients, we demonstrate a positive, non-linear relationship between PA and mental
405	health in CPP.
406	Ethics approval and informed consent
407	The study was approved by the Institutional Review Board (IRB) of the Icahn School of
408	Medicine at Mount Sinai (IRB# STUDY-22-01002) and all participants provided informed
409	consent.
410	Data availability
411	The data collection for the parent grant is currently ongoing. After completion of the
412	active grant period, the data produced in the present study will be made available upon
413	reasonable request to the corresponding author.
414	Funding
415	This study was supported by a grant award from the Eunice Kennedy Shriver National
416	Institute Of Child Health & Human Development of the National Institutes of Health (Award

417	Number: R01HD108263, PI=Ensari). The content does not necessarily represent the official			
418	views of the National Institutes of Health. Additionally, this research was supported by the T32			
419	grant 1T32GM146636.			
420		Authors' contributions		
421		All authors contributed significantly to the work presented in this manuscript, including		
422	the	conception, study design, execution, acquisition of data, analysis and interpretation. Each		
423	aut	hor reviewed this article and agree to take responsibility for the contents of this article.		
424		References		
425	1.	Latthe P, Latthe M, Say L, Gülmezoglu M, Khan KS. WHO systematic review of prevalence		
426		of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health.		
427		2006;6(1):177. doi:10.1186/1471-2458-6-177		
428	2.	Ahangari A. Prevalence of Chronic Pelvic Pain AmongWomen: An Updated Review. Pain		
429		Physician. 2014;2;17(2;3):E141-E147. doi:10.36076/ppj.2014/17/E141		
430	3.	Hutton D, Mustafa A, Patil S, et al. The burden of Chronic Pelvic Pain (CPP): Costs and		
431		quality of life of women and men with CPP treated in outpatient referral centers. Raimondo		
432		D, ed. PLOS ONE. 2023;18(2):e0269828. doi:10.1371/journal.pone.0269828		
433	4.	Till SR, As-Sanie S, Schrepf A. Psychology of Chronic Pelvic Pain: Prevalence,		
434		Neurobiological Vulnerabilities, and Treatment. Clin Obstet Gynecol. 2019;62(1):22-36.		
435		doi:10.1097/GRF.0000000000000412		
436	5.	Ayorinde AA, Macfarlane GJ, Saraswat L, Bhattacharya S. Chronic Pelvic Pain in Women:		
437		An Epidemiological Perspective. Womens Health. 2015;11(6):851-864.		

- 438 doi:10.2217/whe.15.30
- 439 6. Meltzer-Brody S, Leserman J. Psychiatric Comorbidity in Women with Chronic Pelvic Pain.
- 440 *CNS Spectr.* 2011;16(2):29-35. doi:10.1017/S1092852912000156
- 441 7. Till SR, Nakamura R, Schrepf A, As-Sanie S. Approach to Diagnosis and Management of
- 442 Chronic Pelvic Pain in Women. *Obstet Gynecol Clin North Am.* 2022;49(2):219-239.
- 443 doi:10.1016/j.ogc.2022.02.006
- 8. Sheng J, Liu S, Wang Y, Cui R, Zhang X. The Link between Depression and Chronic Pain:
- 445 Neural Mechanisms in the Brain. *Neural Plast.* 2017;2017:1-10. doi:10.1155/2017/9724371
- 446 9. The Initial Management of Chronic Pelvic Pain. Published online 2012.
- 10. Kerns RD, Burgess DJ, Coleman BC, et al. Self-Management of Chronic Pain:
- 448 Psychologically Guided Core Competencies for Providers. *Pain Med.* 2022;23(11):1815-
- 449 1819. doi:10.1093/pm/pnac083
- 450 11. Leonardi M, Horne AW, Vincent K, et al. Self-management strategies to consider to combat
- 451 endometriosis symptoms during the COVID-19 pandemic. *Hum Reprod Open*.
- 452 2020;2020(2):hoaa028. doi:10.1093/hropen/hoaa028
- 453 12. Nonopioid Therapies for Pain Management | Overdose Prevention | CDC.
- 454 13. CDC Clinical Practice Guideline for Prescribing Opioids for Pain United States, 2022 |
  455 MMWR.
- 456 14. Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical activity and
- 457 exercise for chronic pain in adults: an overview of Cochrane Reviews. Cochrane Pain,
- 458 Palliative and Supportive Care Group, ed. *Cochrane Database Syst Rev.* 2017;2020(2).

15. Gilanyi YL, Wewege MA, Shah B, et al. Exercise Increases Pain Self-efficacy in Adults

459 doi:10.1002/14651858.CD011279.pub3

460

461	With Nonspecific Chronic Low Back Pain: A Systematic Review and Meta-analysis. $J$
462	Orthop Sports Phys Ther. 2023;53(6):335-342. doi:10.2519/jospt.2023.11622
463	16. Kalapurakkel S, A. Carpino E, Lebel A, E. Simons L. "Pain Can't Stop Me": Examining
464	Pain Self-Efficacy and Acceptance as Resilience Processes Among Youth With Chronic
465	Headache. J Pediatr Psychol. 2015;40(9):926-933. doi:10.1093/jpepsy/jsu091
466	17. Ensari I, Lipsky-Gorman S, Horan EN, Bakken S, Elhadad N. Associations between physical
467	exercise patterns and pain symptoms in individuals with endometriosis: a cross-sectional
468	mHealth-based investigation. BMJ Open. 2022;12(7):e059280. doi:10.1136/bmjopen-2021-
469	059280
470	18. Ensari I, Pichon A, Lipsky-Gorman S, Bakken S, Elhadad N. Augmenting the Clinical Data
471	Sources for Enigmatic Diseases: A Cross-Sectional Study of Self-Tracking Data and Clinical
472	Documentation in Endometriosis. Appl Clin Inform. 2020;11(05):769-784. doi:10.1055/s-
473	0040-1718755
474	19. Muller HG, Wu Y, Yao F. Continuously additive models for nonlinear functional regression.
475	Biometrika. 2013;100(3):607-622. doi:10.1093/biomet/ast004
476	20. Goldsmith J, Bobb J, Crainiceanu CM, Caffo B, Reich D. Penalized Functional Regression. J
477	Comput Graph Stat. 2011;20(4):830-851. doi:10.1198/jcgs.2010.10007
478	21. Manning JR, Notaro GM, Chen E, Fitzpatrick PC. Fitness tracking reveals task-specific

479 associations between memory, mental health, and physical activity. *Sci Rep.* 

480 2022;12(1):13822. doi:10.1038/s41598-022-17781-0

- 481 22. Hirten RP, Danieletto M, Landell K, et al. Development of the ehive Digital Health App:
- 482 Protocol for a Centralized Research Platform. *JMIR Res Protoc*. 2023;12:e49204.
- 483 doi:10.2196/49204
- 484 23. Hays RD, Schalet BD, Spritzer KL, Cella D. Two-item PROMIS® global physical and
- 485 mental health scales. *J Patient-Rep Outcomes*. 2017;1(1):2. doi:10.1186/s41687-017-0003-8
- 486 24. Global Health Scoring Manual. Published online August 15, 2021.
- 487 25. Elsman EBM, Roorda LD, Crins MHP, Boers M, Terwee CB. Dutch reference values for the
- 488Patient-Reported Outcomes Measurement Information System Scale v1.2 Global Health
- 489 (PROMIS-GH). J Patient-Rep Outcomes. 2021;5(1):38. doi:10.1186/s41687-021-00314-0
- 490 26. Master H, Annis J, Huang S, et al. Association of step counts over time with the risk of
- 491 chronic disease in the All of Us Research Program. *Nat Med.* 2022;28(11):2301-2308.
- 492 doi:10.1038/s41591-022-02012-w
- 493 27. Perry AS, Annis JS, Master H, et al. Association of Longitudinal Activity Measures and
- 494 Diabetes Risk: An Analysis From the National Institutes of Health *All of Us* Research
- 495 Program. J Clin Endocrinol Metab. 2023;108(5):1101-1109. doi:10.1210/clinem/dgac695
- 496 28. Beagle AJ, Tison GH, Aschbacher K, Olgin JE, Marcus GM, Pletcher MJ. Comparison of
- 497 the Physical Activity Measured by a Consumer Wearable Activity Tracker and That
- 498 Measured by Self-Report: Cross-Sectional Analysis of the Health eHeart Study. *JMIR*
- 499 *MHealth UHealth*. 2020;8(12):e22090. doi:10.2196/22090
- 500 29. Troiano RP, Berrigan D, Dodd KW, Mâsse LC, Tilert T, Mcdowell M. Physical Activity in

- the United States Measured by Accelerometer. *Med Sci Sports Exerc*. 2008;40(1):181-188.
- 502 doi:10.1249/mss.0b013e31815a51b3
- 503 30. Rose M, Bjorner JB, Gandek B, Bruce B, Fries JF, Ware JE. The PROMIS Physical
- 504 Function item bank was calibrated to a standardized metric and shown to improve
- 505 measurement efficiency. *J Clin Epidemiol*. 2014;67(5):516-526.
- 506 doi:10.1016/j.jclinepi.2013.10.024
- 507 31. Melzack R. The short-form McGill pain questionnaire. *Pain*. 1987;30(2):191-197.
- 508 doi:10.1016/0304-3959(87)91074-8
- 509 32. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale
- 510 for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire
- 511 (MPQ), Short Form McGill Pain Questionnaire (SF MPQ), Chronic Pain Grade Scale
- 512 (CPGS), Short Form 36 Bodily Pain Scale (SF 36 BPS), and Measure of Intermittent and
- 513 Constant Osteoarthritis Pain (ICOAP). *Arthritis Care Res.* 2011;63(S11).
- 514 doi:10.1002/acr.20543
- 515 33. Lukacz ES, Lawrence JM, Burchette RJ, Luber KM, Nager CW, Galen Buckwalter J. The
- 516 use of Visual Analog Scale in urogynecologic research: A psychometric evaluation. *Am J*
- 517 *Obstet Gynecol.* 2004;191(1):165-170. doi:10.1016/j.ajog.2004.04.047
- 518 34. Creinin MD. Pain Associated With Cervical Priming for First-Trimester Surgical Abortion:
- 519 A Randomized Controlled Trial. *Obstet Gynecol*. 2021;138(4):680-680.
- 520 doi:10.1097/AOG.00000000004552
- 521 35. Bakdash JZ, Marusich LR. Repeated Measures Correlation. *Front Psychol.* 2017;8:456.

522 doi:10.3389/fpsyg.2017.00456

- 523 36. Simon Wood <simon.wood@r-project.org>. mgcv: Mixed GAM Computation Vehicle with
- 524 Automatic Smoothness Estimation. Published online October 4, 2000:1.9-1.
- doi:10.32614/CRAN.package.mgcv
- 526 37. Leavitt MO. 2008 Physical Activity Guidelines for Americans.
- 527 38. Tudor-Locke C, Craig CL, Thyfault JP, Spence JC. A step-defined sedentary lifestyle index:
- 528 <5000 steps/day. *Appl Physiol Nutr Metab*. 2013;38(2):100-114. doi:10.1139/apnm-2012-
- **529** 0235
- 530 39. Tudor-Locke C, Hatano Y, Pangrazi RP, Kang M. Revisiting "How Many Steps Are
- 531 Enough?" *Med Sci Sports Exerc*. 2008;40(7):S537-S543.
- 532 doi:10.1249/MSS.0b013e31817c7133
- 40. *Physical Activity Guidelines for Americans, 2nd Edition*. US Department of Health and
  Human Services; 2018.
- 535 41. Fine PG. Long-Term Consequences of Chronic Pain: Mounting Evidence for Pain as a
- 536 Neurological Disease and Parallels with Other Chronic Disease States. *Pain Med.*
- 537 2011;12(7):996-1004. doi:10.1111/j.1526-4637.2011.01187.x
- 538 42. De La Rosa JS, Brady BR, Ibrahim MM, et al. Co-occurrence of chronic pain and
- anxiety/depression symptoms in U.S. adults: prevalence, functional impacts, and
- 540 opportunities. *Pain*. 2024;165(3):666-673. doi:10.1097/j.pain.000000000003056
- 43. Sachs MK, Dedes I, El-Hadad S, et al. Physical Activity in Women with Endometriosis: Less
- or More Compared with a Healthy Control? *Int J Environ Res Public Health.*

## 543 2023;20(17):6659. doi:10.3390/ijerph20176659

- 544 44. Chen J. The associations of chronic pain and 24-h movement behaviors with incident mental
- 545 disorders: evidence from a large-scale cohort study. Published online 2024.
- 546 45. Zhang W, Singh SP, Clement A, Calfee RP, Bijsterbosch JD, Cheng AL. Improvements in
- 547 Physical Function and Pain Interference and Changes in Mental Health Among Patients
- 548 Seeking Musculoskeletal Care. *JAMA Netw Open*. 2023;6(6):e2320520.
- 549 doi:10.1001/jamanetworkopen.2023.20520
- 550 46. Dowding C, Mikocka Walus A, Skvarc D, et al. The temporal effect of emotional distress
- on psychological and physical functioning in endometriosis: A 12 month prospective study.
- 552 *Appl Psychol Health Well-Being*. 2023;15(3):901-918. doi:10.1111/aphw.12415

# 554 Table 1. Study sample demographics.

555

Variable	N	Mean or %
Age (years)	72	35
Sex	76	
female	76	100%
male	0	0%
Employment status	75	
employed	57	76%
other	7	9%
unemployed	11	15%
Marital status	76	
divorce	6	8%
married	35	46%
single	35	46%
Psychiatric		
diagnosis	76	
None	55	72%
At least 1	21	28%
Race/Ethnicity	76	
asian	8	11%
black	11	14%
hispanic or latino	13	17%
mixed	7	9%
unknown	5	7%
white	32	42%

Table 2. Average weekly and daily measures across the study. The average was taken of the

559 participant means for each repeated measure.

Variable	N	Mean or %
Mean MVPA	76	38
Mean steps	76	8313
Mean MPQ-VAS	75	34
Mean phys. func. T-score	73	45
Mean GMH T-score	75	42
Mean GMH T Category	75	
Poor	3	4%
Fair	29	39%
Good	29	39%
Very Good	8	11%
Excellent	6	8%



# Mean PROMIS GMH and physical functioning T-scores

565 - =45.19, 95% CI: 43.52-46.853, M=50, t = -5.758, p < .001) means were

significantly different than the general population.





Weekly MVPA (minutes)

#### 578 values.



579 580 Figure 3. Repeated measures correlations for weekly measures. MVPA=moderate-to-vigorous

- 581 physical activity; Phys. Func. T = physical functioning T-score; MPQ-VAS=McGill Pain
- Questionnaire-VAS; Global Mental Health T=GMH-T 582







- 624 predicted sample GMH-T mean. **B**) Coefficients and confidence intervals for scalar predictors of
- 625 the model. C) Random effect of participant, with each dot representing predicted mean GMH-T
- 626 for that participant.
- 627

# **Supplemental Tables**

## 

**Table S1.** Smooth predictors of the PFR model.

## 

Predictor	edf	Ref.df	F	p-value
t2(MVPA.tmat,MVPA.omat):L.MVPA	2.23222202	2.40665028	18.9885386	4.0841E-06
s(month_cos.tmat):L.month_cos	2.00001858	2.00003559	0.48641865	0.61566209
s(month_sin.tmat):L.month_sin	2.5591852	2.8159533	0.63612865	0.59048914
s(Participant)	33.4252443	57	2.75714802	1.5399E-06
s(Week)	5.2859E-05	1	5.0264E-06	0.96005532

## 

 Table S2. Point estimates for smooth terms.

Predictor	Estimate	SE
scale(pfr_age)	-1.1946	0.4629
t2(MVPA.tmat,MVPA.omat):L.MVPA.1	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.2	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.3	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.4	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.5	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.6	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.7	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.8	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.9	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.10	0	0.0012

	1	1
t2(MVPA.tmat,MVPA.omat):L.MVPA.11	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.12	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.13	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.14	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.15	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.16	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.17	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.18	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.19	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.20	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.21	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.22	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.23	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.24	0	0.0013
t2(MVPA.tmat,MVPA.omat):L.MVPA.25	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.26	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.27	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.28	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.29	0	0.0012
t2(MVPA.tmat,MVPA.omat):L.MVPA.30	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.31	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.32	0	0.001

	1	1
t2(MVPA.tmat,MVPA.omat):L.MVPA.33	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.34	0	0.001
t2(MVPA.tmat,MVPA.omat):L.MVPA.35	1.0687	0.0317
t2(MVPA.tmat,MVPA.omat):L.MVPA.36	0.0002	0.1151
t2(MVPA.tmat,MVPA.omat):L.MVPA.37	-0.123	0.0037
t2(MVPA.tmat,MVPA.omat):L.MVPA.38	0.0028	0.115
t2(MVPA.tmat,MVPA.omat):L.MVPA.39	-1.3998	0.0415
t2(MVPA.tmat,MVPA.omat):L.MVPA.40	0.0332	0.1141
t2(MVPA.tmat,MVPA.omat):L.MVPA.41	-0.2206	0.0066
t2(MVPA.tmat,MVPA.omat):L.MVPA.42	-0.0057	0.1145
t2(MVPA.tmat,MVPA.omat):L.MVPA.43	10.0619	0.2981
t2(MVPA.tmat,MVPA.omat):L.MVPA.44	0.0442	0.1032
t2(MVPA.tmat,MVPA.omat):L.MVPA.45	0.2974	0.0781
t2(MVPA.tmat,MVPA.omat):L.MVPA.46	0.5677	0.2809
t2(MVPA.tmat,MVPA.omat):L.MVPA.47	-0.5547	0.0165
t2(MVPA.tmat,MVPA.omat):L.MVPA.48	0.6484	0.387
s(pfr_month_cos.tmat):L.pfr_month_cos.1	-0.0001	0.2867
s(pfr_month_cos.tmat):L.pfr_month_cos.2	-0.0001	0.2627
s(pfr_month_cos.tmat):L.pfr_month_cos.3	-0.0002	0.623
s(pfr_month_cos.tmat):L.pfr_month_cos.4	0.0003	0.7492
s(pfr_month_cos.tmat):L.pfr_month_cos.5	0.0002	0.5422
s(pfr_month_cos.tmat):L.pfr_month_cos.6	-1.6094	1.8354

1	1	1
s(pfr_month_cos.tmat):L.pfr_month_cos.7	-3.1231	5.9218
s(pfr_month_sin.tmat):L.pfr_month_sin.1	-8.7097	71.675
s(pfr_month_sin.tmat):L.pfr_month_sin.2	-1.0972	65.6637
s(pfr_month_sin.tmat):L.pfr_month_sin.3	0.0284	156.1398
s(pfr_month_sin.tmat):L.pfr_month_sin.4	12.0161	187.3235
s(pfr_month_sin.tmat):L.pfr_month_sin.5	7.3255	135.9212
s(pfr_month_sin.tmat):L.pfr_month_sin.6	19.7849	30.3586
s(pfr_month_sin.tmat):L.pfr_month_sin.7	6.1957	25.4692
s(pfr_participant).1	-0.8195	3.2219
s(pfr_participant).2	-3.3994	2.33
s(pfr_participant).3	-0.3429	3.0436
s(pfr_participant).4	-1.9507	1.8907
s(pfr_participant).5	-3.1004	1.8541
s(pfr_participant).6	2.7715	1.7634
s(pfr_participant).7	-4.7251	2.5942
s(pfr_participant).8	6.4256	2.302
s(pfr_participant).9	-2.2581	1.7001
s(pfr_participant).10	2.5425	2.4007
s(pfr_participant).11	-5.2992	2.2013
s(pfr_participant).12	7.0277	3.3273
s(pfr_participant).13	2.9095	2.0834
s(pfr_participant).14	1.1844	1.7011

	1	1
s(pfr_participant).15	-0.7041	3.3855
s(pfr_participant).16	3.6399	1.6518
s(pfr_participant).17	1.327	3.2448
s(pfr_participant).18	0.2492	1.9396
s(pfr_participant).19	-0.6143	1.7548
s(pfr_participant).20	-3.9002	1.8232
s(pfr_participant).21	-3.2474	1.81
s(pfr_participant).22	3.3082	2.3462
s(pfr_participant).23	-1.9553	2.7352
s(pfr_participant).24	0.4892	3.3464
s(pfr_participant).25	-1.0614	2.0089
s(pfr_participant).26	7.3399	1.7229
s(pfr_participant).27	-2.2067	3.3497
s(pfr_participant).28	-2.5714	2.4798
s(pfr_participant).29	4.0968	2.4943
s(pfr_participant).30	3.2534	2.0713
s(pfr_participant).31	-1.0354	2.924
s(pfr_participant).32	1.6512	2.4759
s(pfr_participant).33	0.0849	1.7427
s(pfr_participant).34	0.9219	3.3273
s(pfr_participant).35	-1.5758	1.8535
s(pfr_participant).36	-1.1452	2.757

	1	1
s(pfr_participant).37	7.3676	2.7764
s(pfr_participant).38	0.1432	3.0061
s(pfr_participant).39	-0.5169	2.8012
s(pfr_participant).40	-2.5837	3.4357
s(pfr_participant).41	-2.4264	1.8566
s(pfr_participant).42	7.4204	2.7515
s(pfr_participant).43	3.701	3.2246
s(pfr_participant).44	-2.3142	2.7271
s(pfr_participant).45	-1.4783	1.8362
s(pfr_participant).46	-0.8119	3.4236
s(pfr_participant).47	-2.91	2.2243
s(pfr_participant).48	-2.3047	2.7677
s(pfr_participant).49	-1.9364	2.7055
s(pfr_participant).50	-0.8793	3.229
s(pfr_participant).51	-1.9784	3.0708
s(pfr_participant).52	-8.8145	1.9939
s(pfr_participant).53	-0.1424	2.7878
s(pfr_participant).54	-4.7399	2.6715
s(pfr_participant).55	11.8348	1.8121
s(pfr_participant).56	-0.0268	3.1258
s(pfr_participant).57	-0.9704	1.8023
s(week).1	0	0.0008

#### 

## 

# Table S3. Linear predictors for the PFR model.

## 

Predictor	Estimate	SE	T.value	P.value
(Intercept)	2.9429	0.0872	33.752	0
MPQ-VAS	-1.16	0.4964	-2.3368	0.0206
Physical Functioning	2.2409	0.598	3.7475	0.0002
Psychiatric Diagnosis	0.2181	0.8874	0.2458	0.8061
Employed	4.0117	1.0939	3.6674	0.0003
Employed - Other	6.0273	1.2929	4.6617	0
Divorced	0.3939	1.8963	0.2077	0.8357
Married	3.5996	0.8582	4.1946	0
Age	-1.1946	0.4629	-2.5804	0.0107